Nirogacestat is an Orally Active γ-secretase Inhibitor for Desmoid Tumors Research
On November 27, 2023, the Food and Drug Administration approved Nirogacestat for adult patients with progressing desmoid tumors who require systemic treatment. Nirogacestat blocks the activity of an enzyme called…